http://www.raredr.com/videos/phase-3-data-amifampridine-lems
Summary of the Phase 3 Data for Amifampridine Phosphate to Treat LEMS




In this exclusive interview with Rare Disease Report, Shin Oh, MD, of University of Alabama at Birmingham summarizes the clinical data available supporting the use of amifampridine phosphate (Firdapse) to treat patients with Lambert-Eaton myasthenic syndrome (LEMS).

LEMS is a rare autoimmune disease that can be severely disabling, with the primary symptoms being severe muscle weakness.

For more information, visit http://catalystpharma.com/
Printer Printing...
$content$